Ulcerative Colitis Resource Center
The Ulcerative Colitis Resource Center covers the latest information on the diagnosis, management and treatment of ulcerative colitis, as well as up-to-date material on future research.
Imuldosa snags FDA approval as fifth Stelara biosimilar in mounting market logjam
The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.
Tulisokibart bests placebo, may yield ‘important clinical benefit’ via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to a new study that also incorporated a predictive biomarker for response.
F. prausnitzii may serve as marker for thiamine response in quiescent IBD, chronic fatigue
An abundance of Faecalibacterium prausnitzii or Roseburia hominis may predict the effectiveness of high-dose thiamine treatment to alleviate chronic fatigue in quiescent inflammatory bowel disease, according to research.
First-line treatment with vedolizumab linked to fewer hospitalizations, surgeries in IBD
The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.
Initial dose of infliximab 5 mg/kg ‘should be adequate’ in most cases of acute severe UC
No significant differences were reported in clinical response at day 7 between 5 mg/kg and 10 kg/kg doses of infliximab in acute severe ulcerative colitis, nor were there differences in intensified, accelerated or standard dosing at month 3.
Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi
The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.
Filgotinib maintains remission, improves quality of life over 4 years in UC
Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.
Cardiovascular risk assessment recommended before use of small-molecule drugs in IBD
Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.
Vedolizumab improves clinical outcomes, induces mucosal healing in UC, chronic pouchitis
Vedolizumab not only induced endoscopic improvements in patients with chronic pouchitis, but also appeared to improve clinical outcomes at week 34, especially in those who achieved mucosal healing at week 14, research showed.
Skyrizi bests placebo in clinical remission as induction, maintenance therapy for UC
Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.